Advertising, Marketing & Sales

Along with its 2024 full-year and fourth-quarter results – both down slightly – the Los Angeles-based firm on 19 February announced its board appointed Stephan Gratziani, president since January 2024, as CEO effective 1 May.

Recent court cases initiated by the Swiss medicines regulator against “unbalanced” media reporting on GLP-1 drugs for weight loss highlights its zero tolerance for any form of misinformation that compromises patient safety.

In recent US consumer health space rebranding, VEGA pays homage to celestial origins; AN Performance formulations launched with Chiquita co-branding; Crown simplifies Blue Lizard Australian Sunscreen portfolio with products tailored to life stages; and AMMD packaging shows a modern and elevated look.

Brands should “remain flexible and also explore ways to leverage this trend through innovation, consumer education and strategic retailer partnerships,” says Lauren Alexander of market research firm Emerson Group. “This is not a fad,” says Rick Polito of the Nutrition Business Journal.

US sector expands as Else Nutrition branching out from infant and children’s products with an adult shake and Premier Protein brand extends with Indulgence line. Abbott reports 4% adult nutrition sales growth for 2024.

Industry’s results from October-December period start on 22 January with Procter & Gamble reporting its fiscal year 2025 second-quarter numbers and Abbott with its 2024 full-year and fourth-quarter information.

“We have made significant strides in finding new ways to return money to consumers, but a fix to our 13(b) authority is badly needed,” says Sam Levine.

FTC seeks comment on three proposals to “strengthen the agency’s tools to curb deceptive earnings claims in industries where they are pervasive: multi-level marketing programs and money-making opportunities.” However, Republican members say they’ll reconsider the proposals as a majority after Trump takes office.

Final rule’s requirement that ACNU formulations also remain available as Rx generics could limit revenues for marketers of the nonprescription drugs while approvals of ACNU applications from studies with participants having drugs delivered to their homes may require marketers to limit distribution to direct-to-consumer without clearance for sales in retail stores.

National Advertising Division found multiple faults with Oral Essentials’ evidence for claim, including that an in vitro study the firm conducted on “mouse cells is not dispositive of whether the same product would have any adverse effects on humans under real world conditions.”